← Back to Clinical Trials
Recruiting NCT04546945
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Trial Parameters
Condition Hematologic Malignancies
Sponsor Asmaa Hassan mohamed Abdel Mawjoud
Study Type OBSERVATIONAL
Phase N/A
Enrollment 38
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2027-03-20
Completion 2027-06-30
Interventions
CD56
Brief Summary
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Eligibility Criteria
Inclusion Criteria: * Patients with hematologic malignancies. * Newly diagnosed Exclusion Criteria: * Patients with hematologic disorders other than hematologic malignancies.
Related Trials
NCT06665100
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respir
View Trial →
NCT06028828
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
View Trial →
NCT04546945
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
View Trial →